AN2 Therapeutics, Inc.

AN2 Therapeutics, Inc.

ANTX·NASDAQ

$4.28

+3.9%
HealthcareBiotechnology

AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.

At a Glance

Live Snapshot
Market Cap$117.27M
EPS-1.1600
P/E Ratio-3.69
Earnings Date08/06/2026

antx

Net Interest Income

Last Annual Value

2.93M

3-Year CAGR

52%

5-Year CAGR

296%

10-Year CAGR

%

AN2 Therapeutics, Inc.

AN2 Therapeutics, Inc. Competitors Analysis of Net Interest Income

ANTX · NASDAQ
CompanyNet Interest Income
CAGR 3Y
CAGR 5Y
CAGR 10Y
2.93M
N/A111.7%N/A 
314.00K
154.7%N/AN/A
-6.81M
N/AN/AN/A
QTTB logo
Q32 Bio Inc.
NASDAQ:QTTB
1.10M
N/A42.8%N/A
AN2 Therapeutics, Inc.

AN2 Therapeutics, Inc. Fair Value Envelope

ANTX · NASDAQ

Our analysis suggests that ANTX has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $4.2797, this represents a potential HIDDEN relative to our calculated worth for AN2 Therapeutics, Inc..

Intrinsic Value
Current Price: $4.2797